Glycogen Storage Disease Market

Market Overview:

The 7 major glycogen storage disease markets are expected to exhibit a CAGR of 5.76% during 2024-2034.

The glycogen storage disease market has been comprehensively analyzed in IMARC's new report titled "Glycogen Storage Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Glycogen storage disease, also known as glycogenosis, refers to a group of inherited metabolic disorders that affect the body's ability to process and store glycogen properly. As a result, this condition leads to an abnormal accumulation or breakdown of glycogen in various tissues. The common symptoms of the ailment may include an enlarged liver and spleen, low blood sugar, difficulty breathing, muscle weakness, growth delays or short stature, abnormal levels of fats and proteins in the blood, obesity, liver dysfunction or cirrhosis, mouth sores, heart muscle disease, etc. The diagnosis of this illness typically involves a combination of clinical examination, blood workups to evaluate enzyme activity as well as glycogen levels, and genetic testing. The healthcare provider might also perform imaging studies, such as abdominal ultrasound, to assess the pancreas and liver for signs of inflammation, structural abnormalities, or cystic lesions that may be related to the condition. Additionally, a tissue biopsy, along with histochemical staining or electron microscopy, may be necessary to confirm the diagnosis by measuring the levels of glycogen or enzyme present.

The increasing cases of genetic mutations that affect the regulation of specific enzymes, thereby leading to imbalances in glycogen synthesis or breakdown, are primarily driving the glycogen storage disease market. In addition to this, the widespread adoption of enzyme replacement therapy, which involves administering a synthetic form of the deficient enzyme intravenously or orally, is also propelling the market growth. Furthermore, the inflating utilization of xanthine oxidase inhibitors, including allopurinol and oxypurinol, for reducing the levels of uric acid in the blood and preventing the risk of complications, like gout and kidney problems, is acting as another significant growth-inducing factor. Apart from this, the escalating application of molecular diagnostic techniques, such as direct sequencing, polymerase chain reaction-based assays, hybridization, etc., to provide early detection of the illness, which allows for timely intervention and management, is also creating a positive outlook for the market. Moreover, the emerging popularity of gene therapy for treating the ailment, since it aims to correct the faulty genetic material in patients while restoring normal enzyme function and improving metabolic control, is expected to drive the glycogen storage disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the glycogen storage disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for glycogen storage disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the glycogen storage disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the glycogen storage disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the glycogen storage disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current glycogen storage disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the glycogen storage disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the glycogen storage disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the glycogen storage disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of glycogen storage disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of glycogen storage disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of glycogen storage disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with glycogen storage disease across the seven major markets?
• What is the size of the glycogen storage disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of glycogen storage disease?
• What will be the growth rate of patients across the seven major markets?
   

Glycogen Storage Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for glycogen storage disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the glycogen storage disease market?
• What are the key regulatory events related to the glycogen storage disease market?
• What is the structure of clinical trial landscape by status related to the glycogen storage disease market?
• What is the structure of clinical trial landscape by phase related to the glycogen storage disease market?
• What is the structure of clinical trial landscape by route of administration related to the glycogen storage disease market?